Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab with or without ligufalimab versus pembrolizumab in first-line recurrent/metastatic head and neck squamous cell carcinoma
2025-522996-27-00Phase 3Authorised
- Sponsor
- GORTEC
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Ivonescimab monotherapy, Ivonescimab + ligufalimab and Pembrolizumab control (3 arms). Primary endpoint: Overall survival. Planned start Dec 2025; status: authorised.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-522996-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522996-27-00.